Arlene O Siefker-Radtke
Arlene O Siefker-Radtke is a Professor in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center. She received her M.D. degree from Johns Hopkins University School of Medicine. After an internship and residency at New England Medical Center in Boston she completed a medical oncology fellowship at The University of Texas MD Anderson Cancer Center. It was during this fellowship that she developed an interest in genitourinary malignancies with a focused interest on cancers of the urothelial tract. Currently, she sees approximately 4-8 new patients a week with urothelial cancer and enrolls patients on clinical trials. She has conducted many investigator initiated studies, including Phase I, II, and III trials, and also has collaborated with other investigators on research trials from other institutions. She is known for her neoadjuvant clinical trial designs with translational endpoints including predicting response using gene expression profiling, and for her expertise in developing treatments for rare bladder tumors. She been a clinical co-leader on the MDACC Bladder SPORE for over 10 years. She has also served as a chairperson for the Clinical Research Committee, which evaluates trials for scientific integrity, for three years at MD Anderson. She served on the NCI GU Steering Committee 2008-2014, and is a current member of the NCI Bladder Cancer Task Force.